Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

James Catto, MB, ChB, PhD, University of Sheffield

Videos

Erdafitinib for Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

Daniel Geynisman, MD, Fox Chase Cancer Center

Videos

Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement

03/01/2023

At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

03/01/2023

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Avelumab Maintenance for Urothelial Carcinoma by First-Line Chemotherapy Regimen

02/28/2023

At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.

At the 2023 ASCO GU Cancers...

02/28/2023

Oncology

Andrew Katims, MD, Memorial Sloan Kettering Cancer Center

Videos

Assessing the MSK-ACCESS ctDNA Assay in Node-Positive Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Kyle Rose, MD, Moffitt Cancer Center & Research Institute

Videos

Urinary Tumor DNA for Minimal Residual Disease Detection at Repeat TURBT in Non-Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Aristotelis Bamias, MD, University of Athens

Videos

Atezolizumab Monotherapy vs Chemotherapy for Patients with Metastatic Urothelial Carcinoma

02/17/2023

At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...

At the 2023 ASCO Genitourinary...

02/17/2023

Oncology

Peter O'Donnell, MD, University of Chicago

Videos

Efficacy and Safety of Pembrolizumab for Metastatic Urothelial Carcinoma

01/17/2023

Peter O’Donnell, MD, discusses an analysis from from the KEYNOTE-045 and KEYNOTE-052 trials, showing continued efficacy and safety of pembrolizumab for patients with metastatic urothelial carcinoma after 5 years of follow-up.

Peter O’Donnell, MD, discusses...

01/17/2023

Oncology

Quiz

Quiz: Impact of Chemotherapy Choice on Later Immune Checkpoint Inhibitors for Urothelial Carcinoma

12/01/2022

How did first-line cisplatin versus carboplatin impact the survival of patients receiving immune checkpoint inhibitors in the second-line setting?

How did first-line cisplatin...

12/01/2022

Oncology

Andrea Necchi, MD, San Raffaele Hospital

Videos

3-Year Efficacy of Neoadjuvant Pembrolizumab Before Radical Cystectomy For Muscle-Invasive Bladder Cancer

11/03/2022

Andrea Necchi, MD, shares follow-up data from the phase 2 PURE-01 trial, confirming the sustained efficacy of neoadjuvant pembrolizumab before radical cystectomy in patients with muscle-invasive urothelial bladder cancer.

Andrea Necchi, MD, shares...

11/03/2022

Oncology

Quiz

Quiz: After the use of platinum-based chemotherapy for DRD-biomarker positive patients with urothelial carcinoma, which drug was found to improve PFS according to a phase 2 trial?

10/21/2022

After the use of platinum-based chemotherapy in the first-line setting for DNA repair deficiency-biomarker positive patients with urothelial carcinoma, which drug was found to improve progression-free survival according to a phase 2 trial?

After the use of platinum-based...

10/21/2022

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology